Acrivon Therapeutics (ACRV) Competitors $1.64 +0.09 (+5.48%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACRV vs. ELDN, CLYM, NKTX, SCLX, CABA, LFVN, MIST, AVTX, THTX, and CHRSShould you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Eledon Pharmaceuticals (ELDN), Climb Bio (CLYM), Nkarta (NKTX), Scilex (SCLX), Cabaletta Bio (CABA), Lifevantage (LFVN), Milestone Pharmaceuticals (MIST), Avalo Therapeutics (AVTX), Theratechnologies (THTX), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry. Acrivon Therapeutics vs. Its Competitors Eledon Pharmaceuticals Climb Bio Nkarta Scilex Cabaletta Bio Lifevantage Milestone Pharmaceuticals Avalo Therapeutics Theratechnologies Coherus Oncology Acrivon Therapeutics (NASDAQ:ACRV) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Does the media prefer ACRV or ELDN? In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 2 mentions for Acrivon Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 1.62 beat Acrivon Therapeutics' score of 1.45 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Acrivon Therapeutics Positive Eledon Pharmaceuticals Very Positive Do institutionals & insiders believe in ACRV or ELDN? 71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend ACRV or ELDN? Acrivon Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 817.43%. Eledon Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 319.29%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Acrivon Therapeutics is more favorable than Eledon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Eledon Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, ACRV or ELDN? Acrivon Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Which has stronger valuation & earnings, ACRV or ELDN? Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcrivon TherapeuticsN/AN/A-$80.56M-$2.25-0.73Eledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.04 Is ACRV or ELDN more profitable? Acrivon Therapeutics' return on equity of -50.78% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acrivon TherapeuticsN/A -50.78% -46.08% Eledon Pharmaceuticals N/A -92.51%-38.31% SummaryAcrivon Therapeutics beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Acrivon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACRV vs. The Competition Export to ExcelMetricAcrivon TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.44M$2.55B$5.76B$10.26BDividend YieldN/A56.56%5.88%4.63%P/E Ratio-0.7323.5576.5826.64Price / SalesN/A668.05525.00124.82Price / CashN/A169.4937.1760.46Price / Book0.295.3714.156.31Net Income-$80.56M$32.95M$3.29B$271.01M7 Day Performance0.31%1.60%1.28%2.40%1 Month Performance21.11%4.88%5.01%6.77%1 Year Performance-78.49%-3.70%86.96%27.26% Acrivon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACRVAcrivon Therapeutics3.5712 of 5 stars$1.64+5.5%$15.00+817.4%-81.2%$51.44MN/A-0.7358Positive NewsShort Interest ↓ELDNEledon Pharmaceuticals3.0305 of 5 stars$2.58-4.8%$10.00+287.6%-8.5%$162.28MN/A-2.2110Short Interest ↓CLYMClimb Bio3.7686 of 5 stars$2.47+3.3%$9.00+264.4%N/A$161.96MN/A-3.539Positive NewsNKTXNkarta2.3719 of 5 stars$2.12-6.2%$13.60+541.5%-65.5%$160.51MN/A-1.43140Positive NewsHigh Trading VolumeSCLXScilex2.1994 of 5 stars$22.17-2.8%$455.00+1,952.3%-40.9%$158.59M$56.59M-0.7680Positive NewsCABACabaletta Bio3.0628 of 5 stars$1.68-1.2%$14.50+763.1%-49.5%$155.49MN/A-0.6250Positive NewsLFVNLifevantage3.9784 of 5 stars$11.44-5.5%$30.50+166.6%+7.9%$153.69M$228.53M15.46260High Trading VolumeMISTMilestone Pharmaceuticals2.4495 of 5 stars$1.75-2.8%$5.00+185.7%+28.3%$152.99M$1M-2.0830AVTXAvalo Therapeutics3.8953 of 5 stars$11.41-1.6%$30.00+162.9%+9.9%$152.57M$440K0.0040News CoveragePositive NewsShort Interest ↓THTXTheratechnologiesN/A$3.27flatN/A+132.4%$150.35M$85.87M-17.21140News CoverageShort Interest ↓CHRSCoherus Oncology4.3609 of 5 stars$1.37+6.2%$4.51+229.4%+29.5%$149.93M$272.21M0.88330Positive News Related Companies and Tools Related Companies Eledon Pharmaceuticals Competitors Climb Bio Competitors Nkarta Competitors Scilex Competitors Cabaletta Bio Competitors Lifevantage Competitors Milestone Pharmaceuticals Competitors Avalo Therapeutics Competitors Theratechnologies Competitors Coherus Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACRV) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrivon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACRV Stock Alerts